Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sherry Mori-Vogt"'
Autor:
Vineeth Sukrithan, Heather Armbruster, Sherise Rogers, Sherry Mori Vogt, Cassandra Grenade, Claire Verschraegen, Ye Zhou, Ashima Goyal, Mona Natwa, Akram Hussein, Hallie Barr, Dramane Konate, Rochelle Batdorf, Andrew Brown, Bonnie Williams, Songzhu Zhao, Lai Wei, Menglin Xu, Manisha H Shah, Bhavana Konda
Publikováno v:
PLoS ONE, Vol 19, Iss 5, p e0298824 (2024)
Peptide receptor radionucleotide therapy (PRRT) with 177Lu-dotatate is widely used for the treatment of patients with neuroendocrine tumors (NETs). We analyzed data from 104 patients with NETs treated with 177Lu -dotatate at a US academic center betw
Externí odkaz:
https://doaj.org/article/da237d007c1746b79d20f52d80a9036a
Autor:
Evan E. Gross, Mingjia Li, Ming Yin, Delaney Orcutt, Duncan Hussey, Elliot Trott, Sarah K. Holt, Erin R. Dwyer, Joel Kramer, Kaylee Oliva, John L. Gore, George R. Schade, Daniel W. Lin, Scott S. Tykodi, Evan T. Hall, John A. Thompson, Anish Parikh, Yuanquan Yang, Katharine A. Collier, Abdul Miah, Sherry Mori-Vogt, Megan Hinkley, Amir Mortazavi, Paul Monk, Edmund Folefac, Steven K. Clinton, Sarah P. Psutka
Publikováno v:
Urologic oncology. 41(1)
Cytoreductive nephrectomy (CN) for the treatment of metastatic renal cell carcinoma (mRCC) was called into question following the publication of the CARMENA trial. While previous retrospective studies have supported CN alongside targeted therapies, t
Autor:
Steven K. Clinton, Amir Mortazavi, Abdul Miah, Evan Gross, Edmund Folefac, Evan T. Hall, Katharine Collier, Kaylee Oliva, Paul Monk, Megan Hinkley, Yuanquan Yang, John F. Thompson, John C. Gore, Delaney Orcutt, Joel Kramer, Duncan Hussey, Mingjia Li, Sherry Mori-Vogt, George R. Schade, Scott S. Tykodi, Sarah P. Psutka, Anish B. Parikh, Elliot Trott, Ming Yin, Daniel W. Lin
Publikováno v:
Journal of Urology. 206
INTRODUCTION AND OBJECTIVE:The role of CN in the treatment of mRCC has been questioned with the recent approval of novel systemic therapy (ST) agents and the results of the CARMENA trial. Our objec...
Autor:
Ming Yin, Delaney Orcutt, John L. Gore, Steven K. Clinton, Sherry Mori-Vogt, Amir Mortazavi, Scott S. Tykodi, Abdul Miah, Megan Hinkley, Elliot Trott, Edmund Folefac, Daniel W. Lin, Evan T. Hall, Paul Monk, Katharine Collier, Kaylee Oliva, Yuanquan Yang, Duncan Hussey, Joel Kramer, John F. Thompson, Evan Gross, George R. Schade, Sarah P. Psutka, Anish B. Parikh, Mingjia Li
Publikováno v:
Journal of Urology. 206
INTRODUCTION AND OBJECTIVE:IO/TKI combinations are a new standard of care for the initial treatment (tx) of mRCC. Efficacy and toxicity of such combination regimens beyond the first-line (1L) setti...
Autor:
Ming Yin, Claire F. Verschraegen, Anish B. Parikh, Menglin Xu, Sherry Mori Vogt, Steven K. Clinton, Yuanquan Yang, Tzu-Fei Wang, Edmund Folefac, Sandip H. Patel, Tiffany L. George
Publikováno v:
CancerReferences. 127(6)
Background Some cancer patients who are diagnosed with thromboembolism may require dual treatment with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) and factor Xa inhibitors (low-molecular-weight heparin [LMWH]
Autor:
Steven K. Clinton, Ming Yin, Evan Gross, Anish B. Parikh, Sherry Mori-Vogt, Mingjia Li, Edmund Folefac, Amir Mortazavi, Paul Monk, Sarah P. Psutka, Kaylee Oliva, Yuanquan Yang, Abdul Miah, Joel Kramer, Duncan Hussey, Katharine Collier, Megan Hinkley, Elliott Trott, Delaney Orcutt
Publikováno v:
Journal of Clinical Oncology. 39:e16567-e16567
e16567 Background: ICI/TKI combinations are a new standard of care for the initial treatment (tx) of mRCC. Efficacy and toxicity of such combination regimens beyond the first-line (1L) setting remain unknown. Methods: We retrospectively reviewed char
Autor:
Katharine Collier, Ming Yin, Anish B. Parikh, Mingjia Li, Megan Hinkley, Sherry Mori-Vogt, Abdul Miah, Yuanquan Yang
Publikováno v:
Journal of Clinical Oncology. 39:305-305
305 Background: Although not officially approved, salvage nivolumab plus ipilimumab (nivo/ipi) treatment after prior PD-1/PD-L1 immune checkpoint inhibition is frequently used in metastatic renal cell carcinoma (mRCC). However, very limited data are
Publikováno v:
Journal of Clinical Oncology. 38:e19305-e19305
e19305 Background: Tyrosine kinase inhibitors (TKIs) of vascular endothelial growth factor receptor (VEGFR) may interfere with the coagulation system making patients susceptible to both hemorrhage and thromboembolism. Some cancer patients require dua
Publikováno v:
Blood. 134:3681-3681
Background: Some cancer patients with thromboembolism require dual treatment of VEGFR TKIs and factor Xa inhibitors (direct or indirect), which may contribute to increased bleeding risks. However, the safety of such combination treatment has not been
Autor:
Sherry Mori-Vogt, Marlo Blazer
Publikováno v:
Expert review of anticancer therapy. 13(8)
Chemotherapy-induced nausea and vomiting (CINV) remains both a feared side effect of cancer treatment and a focus of many supportive care initiatives/guidelines. The class of medications known as serotonin receptor antagonists (5-HT3RAs) are integral